Bluebird Bio announces completion of sale to fund managed by Carlyle, SK
Written by Emily J. Thompson, Senior Investment Analyst
Completion of Sale: bluebird bio has completed its sale to Carlyle and SK Capital Partners, resulting in its common stock ceasing to trade publicly.
New Leadership Vision: David Meek, the new CEO, emphasizes a commitment to enhancing commercial execution and expanding access to gene therapies for conditions like sickle cell disease and beta-thalassemia.
Analyst Views on CG
Wall Street analysts forecast CG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CG is 66.70 USD with a low forecast of 51.00 USD and a high forecast of 77.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
6 Buy
4 Hold
1 Sell
Moderate Buy
Current: 66.120
Low
51.00
Averages
66.70
High
77.00
Current: 66.120
Low
51.00
Averages
66.70
High
77.00
About CG
The Carlyle Group Inc. is a global investment company. The Company's segments include Global Private Equity, Global Credit and Carlyle AlpInvest. The Global Private Equity segment advises the Company's buyout, growth, real estate, infrastructure, and natural resources funds. The segment also includes the NGP Carry Funds advised by NGP Energy Capital Management (NGP). The Global Credit segment advises funds and vehicles that pursue investment strategies including insurance solutions, liquid credit, opportunistic credit, direct lending, asset-backed finance, aviation finance, infrastructure credit, cross-platform credit products, and global capital markets. The Carlyle AlpInvest segment advises global private equity programs that pursue secondary purchases and financing of existing portfolios, managed co-investment programs, and primary fund investments. The Carlyle AlpInvest segment helps investors meet their objectives through tailored portfolio construction and investment selection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
